Select a Size
All Photos(8)
About This Item
Empirical Formula (Hill Notation):
MgSO4
CAS Number:
Molecular Weight:
120.37
NACRES:
NA.21
PubChem Substance ID:
UNSPSC Code:
12352302
EC Number:
231-298-2
MDL number:
assay:
≥99.5%
grade:
anhydrous
form:
powder
Product Name
Magnesium sulfate, anhydrous, free-flowing, Redi-Dri™, ReagentPlus®, ≥99.5%
InChI key
CSNNHWWHGAXBCP-UHFFFAOYSA-L
InChI
1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
SMILES string
[Mg++].[O-]S([O-])(=O)=O
grade
anhydrous
agency
suitable for SM 5210
vapor density
<0.01 (vs air)
vapor pressure
<0.1 mmHg ( 20 °C)
product line
ReagentPlus®
Redi-Dri™
assay
≥99.5%
form
powder
quality
free-flowing
pH
~7.9 (25 °C, 50 g/L)
Quality Level
Looking for similar products? Visit Product Comparison Guide
Related Categories
Application
Magnesium sulfate may be used as a drying agent for organic extracts.
Features and Benefits
- Increased efficiency – Eliminate time and effort of loosening hardened powders
- Safety – Avoid risks of using tools of force to break up clumps
- Economy – Faster preparation and solvation increase productivity and reduce costs
- Assured quality – Excellent, expert-tested quality with no anti-caking agents
- Flexible volumes – Available from research amounts to scale-up quantities
General description
Magnesium sulfate is a magnesium salt with tocolytic ability. Its role to induce an analgesic effect during intraoperative and postoperative periods has been investigated. It is reported to prevent eclampsia. Its ability to remove water from water-miscible solvents by salting-out phase separation has been studied.
Legal Information
ReagentPlus is a registered trademark of Merck KGaA, Darmstadt, Germany
Redi-Dri is a trademark of Sigma-Aldrich Co. LLC
Storage Class
13 - Non Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Lex W Doyle
Current opinion in pediatrics, 24(2), 154-159 (2012-01-10)
Antenatal magnesium sulfate may reduce the excessive rates of cerebral palsy in survivors of very preterm birth. There are five randomized controlled trials of magnesium sulfate therapy given to the mother prior to very preterm birth which have reported neurological
Lex W Doyle et al.
Obstetrics and gynecology, 113(6), 1327-1333 (2009-05-23)
To systematically review rates of neurologic outcomes reported in childhood for the preterm fetus exposed to antenatal magnesium sulfate. We searched the Cochrane Pregnancy and Childbirth Group's Trials Register, CENTRAL (The Cochrane Library 2008, Issue 3), relevant references from retrieved
Robert J Floor et al.
Chembiochem : a European journal of chemical biology, 15(11), 1660-1672 (2014-07-01)
We explored the use of a computational design framework for the stabilization of the haloalkane dehalogenase LinB. Energy calculations, disulfide bond design, molecular dynamics simulations, and rational inspection of mutant structures predicted many stabilizing mutations. Screening of these in small
Claire L O'Brien et al.
Gut, 63(10), 1596-1606 (2014-01-17)
Our aim was to determine whether or not specific microorganisms were transported selectively to lymph nodes in Crohn's disease (CD) by comparing node and mucosal microbial communities in patients and controls. We also sought evidence of dysbiosis and bacterial translocation.
Federica Belluti et al.
ChemMedChem, 9(2), 371-382 (2014-01-10)
A significant improvement in the treatment of trypanosomiases has been achieved with the recent development of nifurtimox-eflornithine combination therapy (NECT). As an alternative to drug combinations and as a means to overcome most of the antitrypanosomatid drug discovery challenges, a
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service